'HepConomics': cost-effective, indeed, but how can we pay for it?
Department of Health Economics, National School of Public Health, Athens, Greece. kathanasakis@esdy.edu.gr.
K
K
Athanasakis
Department of Health Economics, National School of Public Health, Athens, Greece.
I
I
Petrakis
Department of Health Economics, National School of Public Health, Athens, Greece.
J
J
Kyriopoulos
D000998:Antiviral Agents / Q000191:economics* / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000191:economics*; D006801:Humans
D000998:Antiviral Agents